Literature DB >> 9569028

Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells.

C Capoulade1, B Bressac-de Paillerets, I Lefrère, M Ronsin, J Feunteun, T Tursz, J Wiels.   

Abstract

Numerous studies have indicated that inactivation of p53 is one of the essential requirements for the unrestrained growth of tumoral cells. When the status of the p53 gene was examined in various types of lymphoid malignancies, mutations in p53 have been predominantly detected in Burkitt's lymphoma (BL) cells, therefore suggesting that alteration of p53 could specifically contribute to the malignant phenotype of these tumoral cells. In addition to mutations, functional inactivation of p53 can also occur through interaction of the wild-type gene product with various viral or cellular proteins. The cellular MDM2 protein, for example, is able to inhibit p53 tumor suppressor function by concealing its transactivation domain. Mdm2 gene amplification has been described in several types of sarcomas, resulting in overexpression of the MDM2 protein. In this study, we have examined the status of MDM2 and p53 in 20 BL cell lines. Four were found to contain wild-type p53 and to overexpress MDM2 protein. Within these BL cells, both molecules are physically associated since they can be co-precipitated and p53 is inactivated as cells neither arrest in G1 nor enter apoptosis following gamma-radiation. We also report that the high level of the MDM2 protein in BL cells is neither associated with an amplification of the mdm2 gene nor with an elevated level of RNA or an increased protein stability, but is rather due to an enhanced translation ability of the mdm2 RNA. These results indicate that in certain BL cells, overexpression of MDM2 protein regulated at the posttranscriptional level, induces an escape from p53-controlled cell growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9569028     DOI: 10.1038/sj.onc.1201702

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

1.  Induction of MDM2-P2 transcripts correlates with stabilized wild-type p53 in betel- and tobacco-related human oral cancer.

Authors:  R Ralhan; A Sandhya; M Meera; W Bohdan; S K Nootan
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis.

Authors:  C M Eischen; D Woo; M F Roussel; J L Cleveland
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Homologous recombination mediates S-phase-dependent radioresistance in cells deficient in DNA polymerase eta.

Authors:  Nils H Nicolay; Rebecca Carter; Stephanie B Hatch; Niklas Schultz; Remko Prevo; W Gillies McKenna; Thomas Helleday; Ricky A Sharma
Journal:  Carcinogenesis       Date:  2012-07-20       Impact factor: 4.944

4.  Role of the RNA-binding protein La in cancer pathobiology.

Authors:  Gunhild Sommer; Tilman Heise
Journal:  RNA Biol       Date:  2020-07-20       Impact factor: 4.652

Review 5.  The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Authors:  Christine M Eischen; Guillermina Lozano
Journal:  Hum Mutat       Date:  2014-03-06       Impact factor: 4.878

6.  Rac1 targeting suppresses p53 deficiency-mediated lymphomagenesis.

Authors:  Emily E Bosco; Wenjun Ni; Lei Wang; Fukun Guo; James F Johnson; Yi Zheng
Journal:  Blood       Date:  2010-02-23       Impact factor: 22.113

Review 7.  Posttranscriptional regulation of p53 and its targets by RNA-binding proteins.

Authors:  Jin Zhang; Xinbin Chen
Journal:  Curr Mol Med       Date:  2008-12       Impact factor: 2.222

8.  p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.

Authors:  Duonan Yu; Martin Carroll; Andrei Thomas-Tikhonenko
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

9.  BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets.

Authors:  Eric S Calhoun; Jessa B Jones; Raheela Ashfaq; Volkan Adsay; Suzanne J Baker; Virginia Valentine; Paula M Hempen; Werner Hilgers; Charles J Yeo; Ralph H Hruban; Scott E Kern
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

Review 10.  Mechanisms involved in Burkitt's tumor formation.

Authors:  M R Campanero
Journal:  Clin Transl Oncol       Date:  2008-05       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.